Singapur - anglès - HSA (Health Sciences Authority)

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 91.52mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 91.52mg eqv to losartan potassium 100.00mg

Singapur - anglès - HSA (Health Sciences Authority)

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 45.76mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 45.76mg eqv to losartan potassium 50.00mg

Unió Europea - anglès - EMA (European Medicines Agency)

merck sharp & dohme b.v. - daptomycin - gram-positive bacterial infections; bacteremia; soft tissue infections; endocarditis, bacterial - antibacterials for systemic use, - cubicin is indicated for the treatment of the following infections.adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cssti).adult patients with right-sided infective endocarditis (rie) due to staphylococcus aureus.it is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.adult and paediatric (1 to 17 years of age) patients with staphylococcus aureus bacteraemia (sab). in adults, use in bacteraemia should be associated with rie or with cssti, while in paediatric patients, use in bacteraemia should be associated with cssti.daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, cubicin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents.

Unió Europea - anglès - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type 2 diabetes mellitus:janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.janumet is indicated as triple combination therapy with a ppar  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar  agonist.janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Unió Europea - anglès - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

Israel - anglès - Ministry of Health

rafa laboratories ltd - chlormethine as hydrochloride - gel - chlormethine as hydrochloride 160 mcg/g - chlormethine - topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin-directed therapy

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - dexamethasone,hydrocortisone acetate,paraformaldehyde,thymol iodide -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - camphor,lignocaine,parachlorophenol,paraformaldehyde -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - lignocaine,paraformaldehyde -

Unió Europea - anglès - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.